chloroethyl, R^4 is H, R^5 is I, $O(C_1-C_4)$ alkyl or H and R^6 is I, $O(C_1-C_4)$ alkyl or H with the proviso that when R^4 , R^5 , and R^6 are H, R^3 is not ethyl; or a pharmaceutically acceptable salt thereof.

157. (New) A method of treating diabetic retinopathy by increasing the level of TGF-beta in a mammal in need thereof, comprising administering an effective amount of a compound of formula (I):

$$(R^1)(R^2)N(CH_2)_2O$$
 (Z)
 R^3
 (I)

wherein Z is C=O or a covalent bond; Y is H or $O(C_1-C_4)$ alkyl, R^1 and R^2 are individually (C_1-C_4) alkyl or together with N are a saturated heterocyclic group, R^3 is ethyl or chloroethyl, R^4 is H or together with R^3 is $-CH_2-CH_2$ - or -S-, R^5 is I, OH, $O(C_1-C_4)$ alkyl or H with the proviso that when R^4 , R^5 , and R^6 are H, R^3 is not ethyl; or a pharmaceutically acceptable salt thereof.

REMARKS

Applicant respectfully requests that the Preliminary Amendment described herein be entered into the record prior to examination of the above-identified application.

Claims 67-77, 95, 99-103, 108-111, and 118-119 are amended to recite proper antecedent basis.

Support for the amendment to claim 80 is provided in the specification at page 3, lines 8-6; page 5, lines 12-17; page 10, line 10-page 11, lines 1; page 12, lines 11-14; and in claim 80 as

originally filed.

Support for the amendment to claim 81 is found in the specification at page 3, lines 18-20 and claim 81 as originally filed.

Support for the amendment to claim 120 is found in the specification at page 3, lines 5-16; and claim 120 as originally filed.

Support for newly added claim 153 is found in the specification at page 3, line 20-page 4, line 4; and page 9, lines 10-18.

Support for newly added claim 154 is found in the specification at page 4, lines 5-7; and page 5, lines 12-20.

Support for newly added claim 155 is found in the specification at page 5, lines 17-20; page 16, lines 10-13; and page 28-lines 10-12.

Support for newly added claim 156 is found in the specification at page 10, lines 29-31 and page 12, lines 11-14.

Support for newly added claim 157 is found in the specification at page 12, lines 12-14; page 17, lines 4-20; and in originally filed claims 95 and 97.

Respectfully submitted,

DAVID J. GRAINGER ET AL.,

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938 Minneapolis, MN 55402 (612) 373-6959

Janet E. Embretson Reg. No. 39,665

"Express Mail" mailing label number: EL618437376US Date of Deposit: January 4, 2001 This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.